|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
13
|
|
pubmed:dateCreated |
2009-8-17
|
|
pubmed:abstractText |
Using clinical isolates from a recent passive immunization trial with antibody 2G12, we probed the capacity of frequently used neutralization formats - the primary peripheral blood mononuclear cell (PBMC)-based and the TZM-bl cell-based assay systems - to predict in-vivo activity of 2G12.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1473-5571
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
24
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1659-67
|
|
pubmed:dateRevised |
2011-7-29
|
|
pubmed:meshHeading |
pubmed-meshheading:19581791-Antibodies, Monoclonal,
pubmed-meshheading:19581791-Cell Line,
pubmed-meshheading:19581791-Drug Evaluation, Preclinical,
pubmed-meshheading:19581791-HIV Antibodies,
pubmed-meshheading:19581791-HIV Fusion Inhibitors,
pubmed-meshheading:19581791-HIV Infections,
pubmed-meshheading:19581791-HIV-1,
pubmed-meshheading:19581791-Humans,
pubmed-meshheading:19581791-Immunization, Passive,
pubmed-meshheading:19581791-Leukocytes, Mononuclear,
pubmed-meshheading:19581791-Neutralization Tests,
pubmed-meshheading:19581791-Virus Replication
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
HIV sensitivity to neutralization is determined by target and virus producer cell properties.
|
|
pubmed:affiliation |
Institute of Medical Virology, University of Zurich, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
